ILMN
Illumina, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$218.22
−1.55%Year over year
Reported trailing growth
- Revenue
- +4.9%
- EBITDA
- -23.6%
- EBIT
- -30.2%
- EPS
- -31.8%
- Free cash flow
- -8.9%
- Operating cash flow
- -5.1%
Forward estimates
Based on analyst estimates
- Revenue
- +5.6%
- EBITDA
- -6.3%
- EPS
- +5.4%
Three-year CAGR
- Revenue
- -1.8%
- EBITDA
- +301.0%
- EBIT
- +203.7%
- Net income
- +169.5%
- EPS
- +171.3%
- Free cash flow
- +106.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026